Clinical Trial Update: Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial updates alternative dosing regimens of subcutaneous azacitidine in myelodysplastic syndromes with completed results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2010-05-28